Aytu BioPharma Announces AR101 Granted Orphan Designation in Europe for the Treatment of Ehlers-Danlos Syndrome

02.03.2022 - ENGLEWOOD, CO / ACCESSWIRE / March 2, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the European Commission granted orphan designation to AR101 ... Seite 1

Related Keywords

Aytu Biopharma ,Josh Disbrow ,Aytu Biopharma Inc ,Health Technology Assessments ,European Commission ,Drug Administration ,Nasdaq ,Ehlers Danlos Syndrome ,Orphan Medicinal Products ,European Medicines ,